Pulmozyme (rhDNase) in neonates.

Pulmozyme is being used off-label increasingly across institution neonatal intensive care units.

It purges free-floating (extracellular) DNA by ripping it apart and cleaning it out.  Which in refractory atelectasis appears to be one of the contributions to its refractory-ness.

Some limited research[1] suggests it might be beneficial.  Respiratory Therapists may be using this more and more frequently in non-cystic-fibrosis neonates.

Previous research produced positive outcomes.[2]

1. Mackinnon R, Wheeler KI, Sokol J. Endotracheal DNase for atelectasis in ventilated neonates. J Perinatol. 2011;31(12):799-801.
2. Hendriks T, De hoog M, Lequin MH, Devos AS, Merkus PJ. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care. 2005;9(4):R351-6.